DARMSTADT, Germany, Dec. 1, 2016 /PRNewswire/ - Merck, a leading life science and technology company, today announced an expansion of its distribution alliance with Roche to include the polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems, a company acquired by Roche in 2015.
Photo - http://photos.prnewswire.com/prnh/20161122/442165
The addition of the Kapa portfolio strengthens Merck's existing distribution relationship with Roche by providing one of the most complementary suites of high-performance tools for PCR and qPCR available in the industry today.
"The alliance extension with Roche will offer our customers greater access to novel products via our world-class distribution channel," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "These enzymes represent a significant advantage over commercially available DNA polymerases and thus offer the potential for entirely new PCR applications."
Under the terms of the agreement, Merck will employ its sales, marketing and e-commerce expertise and leverage the strength of its relationships with the scientific community to present and distribute Kapa PCR and quantitative PCR reagents and kits. The distribution agreement includes all geographies except the U.S., Japan and Brazil. Financial details were not disclosed.
Roche inked the global exclusive distribution agreement for its Biochemical Reagents portfolio with Sigma-Aldrich in July 2015. Following the acquisition of Sigma-Aldrich by Merck in the same year, this agreement became an important part of Merck, driving growth in its life science business and offering premier brand tools for genomics, proteomics and cell analysis.
The novel PCR enzymes offered under the expanded distribution agreement have improved tolerance to common PCR inhibitors, increased speed and specific activity, and higher fidelity. These characteristics enable higher quality results and improved workflows. i
Transition of Kapa's PCR and qPCR portfolios to Merck is expected to be completed by January 1, 2017. In the interim, these products will continue to be available through existing Kapa channels. For more information, visit www.sigma-aldrich.com/kapa.
i Data on file
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
CONTACT: Neetha Mahadevan +49 6151 72 6328